Literature DB >> 8731944

The application of prostaglandin E1 indirect portal vein angiography and color Doppler ultrasound in patients with post-devascularization portal hypertension.

Z H Peng1, M X Zhang.   

Abstract

The selection of proper treatment is based on identification of the causes of massive hemorrhage of gastrointestinal tract after pericardial devascularization. The combined use of prostaglandin E1 indirect portal vein angiography, DSA of celiac artery and color Doppler can provide detailed information about portal vein system, including the presence of embolism, spongioid changes and devascularization of left gastric vein and left gastric artery and the direction of blood flow. If these techniques failed to reveal the causes of digestive tract bleeding, the endoscopy may show lesions of gastric mucosa, which could be accountable for the bleeding.

Entities:  

Mesh:

Substances:

Year:  1995        PMID: 8731944     DOI: 10.1007/BF02888225

Source DB:  PubMed          Journal:  J Tongji Med Univ        ISSN: 0257-716X


  4 in total

1.  Hemodynamic significance of the paraumbilical vein in portal hypertension: assessment with duplex US.

Authors:  G H Mostbeck; G R Wittich; C Herold; K A Vergesslich; R M Walter; S Frotz; G Sommer
Journal:  Radiology       Date:  1989-02       Impact factor: 11.105

2.  The use of prostaglandin E1 for enhanced visualization of the splanchnic circulation.

Authors:  K Jonsson; S Wallace; E D Jacobson; J H Anderson; J Zornoza; M Granmayeh
Journal:  Radiology       Date:  1977-11       Impact factor: 11.105

3.  Modified distal splenorenal shunt with expanded polytetrafluoroethylene interposition.

Authors:  N Nagasue; Y Ogawa; H Yukaya; S Hirose
Journal:  Surgery       Date:  1985-11       Impact factor: 3.982

4.  Superior mesenteric angiography and blood flow measurement following intra-arterial injection of prostaglandin E1.

Authors:  R A Clark; D P Colley; E D Jacobson; R Herman; G Tyler; D Stahl
Journal:  Radiology       Date:  1980-02       Impact factor: 11.105

  4 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.